Radiation Therapy and Temsirolimus or Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma - Trial NCT01019434
Access comprehensive clinical trial information for NCT01019434 through Pure Global AI's free database. This Phase 2 trial is sponsored by European Organisation for Research and Treatment of Cancer - EORTC and is currently Completed. The study focuses on Brain and Central Nervous System Tumors. Target enrollment is 111 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
European Organisation for Research and Treatment of Cancer - EORTC
Timeline & Enrollment
Phase 2
Oct 01, 2009
Mar 01, 2014
Primary Outcome
Overall survival at 1 year
Summary
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Temsirolimus may
 stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs
 used in chemotherapy, such as temozolomide, work in different ways to stop the growth of
 tumor cells, either by killing the cells or by stopping them from dividing. It is not yet
 known whether radiation therapy is more effective when given together with temsirolimus or
 temozolomide in treating patients with glioblastoma.
 
 PURPOSE: This randomized phase II trial is studying giving radiation therapy together with
 temsirolimus to see how well it works compared with giving radiation therapy together with
 temozolomide in treating patients with newly diagnosed glioblastoma.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT01019434
Non-Device Trial